Larimar Therapeutics’ (LRMR) Buy Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Larimar Therapeutics (NASDAQ:LRMR) in a research note released on Tuesday,Benzinga reports. Guggenheim currently has a $26.00 target price on the stock.

Other research analysts also recently issued research reports about the stock. HC Wainwright upped their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist Financial started coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Robert W. Baird lowered their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday. Eleven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Larimar Therapeutics has a consensus rating of “Buy” and an average target price of $20.22.

Larimar Therapeutics Trading Up 5.6 %

NASDAQ LRMR opened at $2.38 on Tuesday. Larimar Therapeutics has a 1-year low of $2.19 and a 1-year high of $11.20. The company has a 50 day moving average of $3.10 and a 200-day moving average of $5.16. The firm has a market cap of $151.54 million, a price-to-earnings ratio of -2.07 and a beta of 0.99.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16). On average, analysts forecast that Larimar Therapeutics will post -1.15 earnings per share for the current year.

Institutional Trading of Larimar Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of Larimar Therapeutics in the fourth quarter valued at approximately $25,000. Algert Global LLC acquired a new stake in Larimar Therapeutics in the 4th quarter valued at $47,000. China Universal Asset Management Co. Ltd. bought a new stake in Larimar Therapeutics during the 4th quarter worth about $52,000. Graham Capital Management L.P. acquired a new position in shares of Larimar Therapeutics during the 4th quarter worth about $54,000. Finally, ProShare Advisors LLC bought a new position in shares of Larimar Therapeutics in the 4th quarter valued at about $58,000. Institutional investors and hedge funds own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.